Announcement • Jul 31
Biomark Diagnostics Inc. Auditor Raises 'Going Concern' Doubt Biomark Diagnostics Inc. filed its Annual on Jul 29, 2026 for the period ending Mar 31, 2026. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Reported Earnings • Jul 29
Full year 2026 earnings released: CA$0.014 loss per share (vs CA$0.021 loss in FY 2025) Full year 2026 results: CA$0.014 loss per share (improved from CA$0.021 loss in FY 2025). Net loss: CA$1.48m (loss narrowed 23% from FY 2025). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 24
Biomark Diagnostics Secures Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test BioMark Diagnostics Inc. has officially received formal patent allowances from both the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) for its groundbreaking lung cancer early detection technology. BioMark's minimally invasive blood test leverages a newly patented algorithm designed to boost screening rates and catch non-small cell lung cancer (NSCLC) at its earliest, most treatable stages. The clinical validation of BioMark's metabolomics platform is anchored in exceptionally robust data, having already shown immense promise across more than 15,000 blood samples collected throughout Quebec, France, and Germany. The simultaneous allowances from both CIPO and the EPO represent a profound validation of the scientific approach and the clinical significance of the metabolomics platform. These are not peripheral claims; they protect the core metabolic signatures and advanced algorithms driving the screening panel. This vast multi-jurisdictional clinical asset underscores the reliability, reproducibility, and potential of the platform across diverse population groups. BioMark continues to advance corresponding patent applications actively under prosecution in additional major markets, including the United States, China, and Japan, while preparing for the upcoming commercial launch later this year. The dual validation from Canadian and European patent authorities reinforces the scientific novelty, capturing the attention of international stakeholders looking at the latest diagnostic advancements. By securing this solid intellectual property foundation, BioMark is uniquely positioned to accelerate international commercial partnerships, licensing agreements, and engagement with global health systems looking to integrate cutting-edge diagnostics. 
